幽门螺杆菌感染研究的某些进展、管见与思考-细胞与分子生物学研究-CSCIED科技核心评价数据库-手机版

幽门螺杆菌感染研究的某些进展、管见与思考

Some progress, insights and thinking of Helicobacter pylori infection research

ES评分 0 浏览量：712 下载量：0

DOI	10.12208/j.ijcmbr.20220007
刊名	细胞与分子生物学研究 Journal of Cell and Molecular Biology Research
年，卷(期)	2022, 2(1)
作者	廖远泉*,
作者单位	安徽省泾县医院检验科安徽泾县 ;
摘要	幽门螺杆菌（Helicobacter pylori, H. pylori）感染已经在世界很多国家和地区广泛传播流行。其特定的螺旋形体型，细胞毒素相关A基因（Cag A）、空泡细胞毒素A基因（Vac A）等毒力因子是影响H. pylori定植与感染的相关致病因子。H. pylori感染在胃癌的发生发展中可能具有重要作用，但是，迄今尚未确认H. pylori感染是导致胃癌的主要因素。作者综述了相关致病因子及其致病机制的研究进展。值得关注的是亦有临床及实验研究者对于H. pylori感染因子及其感染机制、诊断与治疗等持有不同的认知或岐见。检验医学是一座将基础医学和临床医学连接起来的桥梁。贯彻落实我国重大传染病预防与控制措施, 检验医师应该与临床和预防医学工作者密切协作、共同关注当前H. pylori感染研究的这一重要课题。
Abstract	Helicobacter pylori (H. pylori) infection has spread widely in many countries and regions in the world. Its specific spirochete type, cytotoxin-associated A gene (Cag A), vacuolar cytotoxin A gene (Vac A) and other virulence factors are the relevant pathogenic factors that affect H. pylori colonization and infection. H. pylori infection may play an important role in the occurrence and development of gastric cancer, but so far it has not been confirmed that H. pylori infection is the main factor leading to gastric cancer. The authors reviewed the research progress of related pathogenic factors and their pathogenic mechanisms. It is worth noting that some clinical and experimental researchers hold different cognitions or disagreements about H. pylori infectious agents and their infection mechanisms, diagnosis and treatment. Laboratory medicine is a bridge connecting basic medicine and clinical medicine. To implement the prevention and control measures of major infectious diseases in my country, laboratory physicians should work closely with clinical and preventive medicine workers to pay attention to the important topic of current H. pylori infection research.
关键词	幽门螺杆菌；感染；流行病学；致病因子；细胞毒素；思考
KeyWord	Helicobacter pylori; infection; epidemiology; causative agent; cytotoxin; think
基金项目
页码	26-35

参考文献
相关文献

[1] 前田愼. Helicobacter pyloriの基礎知識
[J]. 臨床檢查 , 2010 , 54 ( 2) : 133-140.

[2] Salama NR, Hartung ML, Muller A. Life the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori
[J]. Nature Reviews Microbiology, 2013,11（6）：385-389.

[3] Naumann M, Sokolova O, Tegtmeyer N, et al. Helicobacter pylori: A paradigm pathogen for subverting host cell signal transmission
[J]. Trends Microbiol, 2017, 25 (4): 316-328.

[4] 廖远泉，王玲玲，郭喜，等. 幽门螺杆菌生物学特征及其感染的实验室检测
[J]. 中华临床实验室管理电子杂志，2020, 8（2）：71-77.

[5] Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection
[J]. Aliment Pharmacol Ther, 2018, 47 (7): 868-876.

[6] 阿孜尔古丽.阿布都克日木，阿布都哈巴尔. 阿布都克日木，刘玉梅，等. 幽门螺杆菌Cag A基因编码蛋白的生物信息学分析
[J]. 中国病原生物学杂志，2018, 13（3）：221-225.

[7] 周雪亮，周渊，朱强，等. 幽门螺旋杆菌的研究进展
[J]. 中国继续医学教育, 2018, 10 (33): 101-104.

[8] 王猛，穆红 . 幽门螺杆菌致病机制与防治研究进展
[J].中华临床实验室管理电子杂志, 2017, 5 (3) : 135-140.

[9] 魏舒纯，党旖旎，彭磊，等. 幽门螺杆菌与胃肠微生态的研究
[J]. 胃肠病学与肝病学杂志，2019, 28（3）：262-266.

[10] 张万岱，胡伏莲，肖树东，等. 中国自然人群幽门螺杆菌感染的流行病学调查
[J]. 现代消化及介入诊疗，2010, 15（5）：265-270.

[11] Liu J, Wang Y, Zhao Q, et al. Prevalence and risk factor for Helicobacter pylori infection in southwest China: a study of health examination participants based on 13C-urea breath test
[J]. Turk J Med Sci, 2017, 47 (5):1456-1462.

[12] Zhang Y，Li J X. Investigation of current infection with Helicobacter pylori in children with gastrointestinal symptoms
[J]. Zhongguo Dang Dai Er Ke Za Zhi，2012，14（9）：675-677.

[13] 黄洁，黄瑛. 儿童幽门螺杆菌感染常见检测方法的比较
[J]. 微生物与感染，2015, 10（4）：257-262.

[14] Hiroi S, Sugano K, Tanaka S, et al. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan ：retrospective observational study and simulation stuily based on real-world data
[J]. BMJ Open, 2017, 7（7）：e015855.

[15] 上村直実. Helicobacter pylori除菌による胃癌予防の可能性
[J]. 日本臨牀，2009, 67 (supp l.1): 810-815.

[16] Sugamo K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis
[J]. Gut , 2015, 64（9）：1353-1367.

[17] 中华医学会消化病学分会幽门螺杆菌学组、幽门螺杆菌胃炎京都全球共识研讨会纪要
[J].中华消化杂志，2016, 36（1）：53-57.

[18] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组，全国幽门螺杆菌研究协作组，第五次全国幽门螺杆菌感染处理共识报告
[J]. 中华消化杂志，2017, 37（6）：364-378.

[19] 刘文忠，幽门螺杆菌是致病菌毋容置疑
[J]. 中华内科杂志，2018, 57（6）：393-396.

[20] 浅香正博. 我が国からの胃癌撲滅は可能か
[J]. 日本臨牀, 2011, 69 (1): 173-182.

[21] Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials
[J]. BMJ, 2014, 348 (10): 3174-3177.

[22] Masaoka T, Suzuki H. Do we need to eradicate Helicobacter pylori in patients with GORD?
[J]. United European Gastroenterol J, 2013, 1 (4): 223-225.

[23] De BE, Ducatelle R, Foss D, et al. Oral glutathione supplementation drastically reduces Helicobacter-induced gastric pathologies
[J]. Sci Rep, 2016, 6 (3):169-172.

[24] 孔繁静, 赵娟. H. pylori感染的消化性溃疡伴胃癌前病变与自噬因子的相关性研究
[J]. 实用癌症杂志, 2016, 31 (7):1065-1068.

[25] Take S，Mizuno M，Ishiki K，et al．Low Incidence of Esophageal Adenocarcinoma After Eradication of Helicobacter pylori in Japan
[ J］．Clin Gastroenterol Hepatol , 2018，16 ( 12) : 1995-1996．

[26] Zhang R G，Duan G C，Fan Q T，et al. Role of Helicobacter pylori infection in pathogenesis of gastric carcinoma
[J]. World J Gastrointest Pathophysiology， 2016，7（1）：97-107.

[27] Zamanl M，Masrour J，Zamani V. Hematologic disorder：a manifestation of Helicobacter pylori infection
[J]. Caspian J Intern Med，2017，8（2）：133-134.

[28] 廖远泉, 鲍旭, 王玲玲. 幽门螺杆菌感染相关因素的研究进展
[J/OL]. 中华临床实验室管理电子杂志, 2022, 10 (2): 121-125.

[29] 肖玲巧，王超，谢成元，等. 幽门螺杆菌Tipα蛋白激活NLRP3炎性小体诱导THP-1细胞分泌IL-1Β和IL-18
[J]. 中国人兽共患病学报，2017, 33（12）：1071-1076.

[30] 胡洁，孙哲，梅林. 幽门螺杆菌细胞毒导致胃癌发生的作用机制
[J]. 中国药理学通报，2014, 30（2）：156-159.

[31] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori
[J]. J Dig Dis，2013, 14（7）：341-349.

[32] De Brito BB, Da Silva FAF, De Melo FF. Role of poly-morphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis
[J]. World J Clin Oncol, 2018, 9 (5): 83-89.

[33] Mcclain MS, Beckett AC. Helicobacter pylori Vacuola-ting Toxin and Gastric Cancer
[J]. Toxins, 2017, 9 (10): 316-333.

[34] Bornschein J, Malfertheiner P, Helicobacter pylori and gastric cancer
[J]. Dig Dis, 2014, 32（3）：249-264.

[35] Timothy L. Helicobacter pylori Diversity and Gastric Cancer Risk
[J]. MBIO, 2016,7（1）：1869-1884.

[36] 丸澤宏之. H. pylori感染からの胃がん発生機構
[J]. 癌と化学療法, 2010 , 37 (1) : 23-27.

[37] Wroblewski LE, Shen L, Ogden S, et al. Helicobacter pylori dysregulation of gastric epithelial tight junctions by urease-mediated myosin Ⅱ activation
[J]. Gastroenterology, 2009, 136 (1): 236-246.

[38] Tsugawa H, Mori H, Matsuzaki J, et al. Nordihydroguaiaretic acid disrupts the antioxidant ability of Helicobacter pylori through the repression of SODB activity in vitro
[J]. Biomed Res Int, 2015, 201（12）：7345-7348.

[39] Dunne C, Dolan B, Clyne M. Factors that mediate colonization of the human stomach by Helicobacter pylori
[J]. World J Gastroenterol, 2014, 20（19）：5610-5624.

[40] Hage N, Howard T, Phillips C, et al. Structural basis of Lewis b antigen binding by the Helicobacter pylori adhesin BabA
[J]. Sci Adv , 2015, 1（7）e1500315.

[41] Worku MK, Sidebotham RL, Walker MM, et al. The relationship between Helicobacter pylori motility, morphology and phase of growth: implications for gastric colonization and pathology
[J]. Microbiology, 1999, 145（10）：2803-2811.

[42] 罗微，王倩，陈铁龙. 幽门螺杆菌鞭毛研究概述
[J]. 中国病原生物学杂志，2015, 10（9）：852-857.

[43] Markelova N. Interaction of Bdellovibrio bacteriovorus with bacteria Campylobacter jejuni and Helicobacter pylori
[J]. Mikrobiologiia, 2010, 79（6）：777-779.

[44] Isomoto H, Moss J, Hiravama T. Pleiotropic actions of Helicobacter pylori vacuolating cytotoxin, VacA
[J]. Tohoku J Exp Med , 2010，22（1）：3-14.

[45] Rudnicka K, Wlodarczyk M, Moran AP, et al. Helicobacter pylori antigens as potential modulators of lymphocytes cytotoxic activity
[J]. MICROBIOL Immunol, 2012, 56（1）：62-75.

[46] Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease
[J]. J Infect Dis, 1999, 179 (6): 1523-1530.

[47] Marshall BJ. Helicobacter pylori in peptic ulcer: have Koch′s postulates been fulfilled?
[J]. Ann Med, 1995, 27 (5): 565-568.

[48] 林俊治. Helicobacter pylori感染と免疫応答
[J]. 臨床檢查 , 2010 , 54 (2):151-157.

[49] 张鑫, 刘纯杰. 幽门螺杆菌感染引起的免疫应答与免疫逃逸机制研究进展. 世界华人消化杂志 2018, 26 (31): 1832-1842 .

[50] El Khadir M, Alaoui BS, Benajah DA, et al. VacA and CagA status as biomarker of two opposite end outcomes of Helicobacter pylori lntection（gastric cancer and duodenal ulcer）in a moroccan population
[J]. pLoS One, 2017,12（10）：e0170616.

[51] Bibi F, Alvi SA, Sawan SA, et al. Detection and genotyping of Helicobacter pylori among gastric ulcer and cancer patients from Saudi Arabia
[J]. Pak J Med Sci , 2017, 33（2）：320-324.

[52] 田新利，刘东，郭玲，等. 幽门螺杆菌胶原蛋白酶Hp PrtC的表达、纯化及结晶尝试
[J].中国病原生物学杂志，2018,13（7）：719-723.

[53] Han S R，Zschausch H C，Meyer H G，et al. Helicobacter pylori：clonal population structure and restricted transmission within families revealed by molecular typing
[J]. J Clin Microbiol，2000，38（10）：3646-3651.

[54] Kibria K M，Hossain M E，Sultana J，et al. The prevalence of mixed Helicobacter pylori infections in symptomatic and asymptomatic subjects in Dhaka，Bangladesh
[J]. Helicobacter，2015，20（5）：397-404.

[55] Shiota S, Suzuki R, Yamaoka Y. The significance of virulence factors in Helicobacter pylori
[J]. J Dig Dis，2013, 14（7）：341-349.

[56] Percival SL, Suleman L. Biofilms and Helicobacter pylori: dissemination and persistence within the environment and host
[J]. World J Gastrointest Pathophysiol，2014, 5（3）：122-132.

[57] Yip HC, Teoh AYB. Importance of timely eradication of Helicobacter pylori to prevent peptic ulcer recurrence and gastric cancer
[J]. Gastrointest Endosc, 2018, 88 (2): 251-252.

[58] 廖远泉, 王玲玲, 郭喜, 等. 幽门螺杆菌感染研究应重视的问题——与“幽门螺杆菌经呼吸道传播的设想”研究者的商榷
[J]. 医学争鸣, 2019, 10 (6): 18-21.

[59] 廖远泉, 鲍旭. 幽门螺杆菌感染全民根除治疗及其对“微生态系统”平衡的影响
[J]. 医学争鸣, 2020, 11 (4): 51-54, 57.

[60] 袁天峰, 吴涛, 刘佳倩, 等. 明辨是非繁荣医学学术思想碰撞助推医学发展—《医学争鸣》杂志刊发重要学术观点评述
[J]. 医学争鸣, 2021, 12 (2): 1-10.

[61] 司小北, 蓝宇, 高岩. 幽门螺杆菌经呼吸道传播的设想
[J]. 医学争鸣, 2018, 9 (2):14-17, 21.

[62] 程永波，姚萍. 幽门螺杆菌感染者需要全民根除治疗吗?
[J]. 医学争鸣, 2017, 8 (5):24-27.

[63] 廖远泉. 贯彻落实我国重大传染病预防与控制措施, 不忘初心开创检验医学新征程
[J]. 实用检验医师杂志, 2021, 13 (3): 139-142.

[64] 廖远泉. 临床实验室技术自动化的发展历程与检验医学科技创新丰硕成果
[J]. 实用检验医师杂志 , 2020, 12 (3): 129-134.

引用本文

廖远泉*. 幽门螺杆菌感染研究的某些进展、管见与思考 [J]. 细胞与分子生物学研究. 2022; 2; (1). 26 - 35.

文献评论

相关学者

相关机构